EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Immunotherapeutic targets in non‐small cell lung cancer

Habib Sadeghirad, Tayyeb Bahrami, Sepideh M Layeghi, Hassan Yousefi, Meysam Rezaei, Seyed R Hosseini-Fard, Payar Radfar, Majid E Warkiani iD, Ken O'Byrne, Arutha Kulasinghe iD

Immunology · 2023-02 · 168 (2) · 256-272

DOI: 10.1111/imm.13562 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology, online erschienen am 25.08.2022. Verfasst von Habib Sadeghirad und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cure Cancer Australia Foundation, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non‐small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5‐year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in‐depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsHumansEndothelial CellsImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

NSCLCTMEimmunotherapynon-small cell lung cancertumour microenvironment

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
  • Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Biochemistry and Molecular Biology, LSUHSC School of Medicine, New Orleans, Louisiana, USA.
  • School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia.
  • Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.

ORCID-Profile: Majid E Warkiani, Arutha Kulasinghe

Förderung

  • Cure Cancer Australia Foundation
  • National Health and Medical Research Council

Zitieren

APA

Sadeghirad, H., Bahrami, T., Layeghi, S. M., Yousefi, H., Rezaei, M., Hosseini-Fard, S. R., Radfar, P., Warkiani, M. E., O'Byrne, K., & Kulasinghe, A. (2023). Immunotherapeutic targets in non‐small cell lung cancer. Immunology, 168(2), 256-272. https://doi.org/10.1111/imm.13562

Vancouver

Sadeghirad H, Bahrami T, Layeghi SM, Yousefi H, Rezaei M, Hosseini-Fard SR, et al. Immunotherapeutic targets in non‐small cell lung cancer. Immunology. 2023;168(2):256-272. doi:10.1111/imm.13562

BibTeX
@article{Sadeghirad2023,
  author = {Sadeghirad, Habib and Bahrami, Tayyeb and Layeghi, Sepideh M and Yousefi, Hassan and Rezaei, Meysam and Hosseini-Fard, Seyed R and Radfar, Payar and Warkiani, Majid E and O'Byrne, Ken and Kulasinghe, Arutha},
  title = {Immunotherapeutic targets in non‐small cell lung cancer},
  journal = {Immunology},
  year = {2023},
  volume = {168},
  number = {2},
  pages = {256--272},
  doi = {10.1111/imm.13562}
}
Kostenlos starten →